TORONTO, ON – When biotech and pharmaceutical companies in Canada’s premier life sciences hub need specialized preclinical contract research organization (CRO) services, Anilocus delivers cutting-edge solutions that drive drug discovery forward. Providing preclinical CRO services to research teams located in the heart of Toronto’s dynamic biotech ecosystem, we provide comprehensive preclinical research support with the local accessibility and regulatory expertise your projects demand.
Your Preclinical CRO Partner in Canada’s Innovation Capital
Toronto’s life sciences sector employs more than 30,000 professionals and contributes over $3.6 billion to the local economy, representing a 24% increase from 2022 and setting a new record for economic output. The Discovery District, a 2.5-square kilometer research park in downtown Toronto’s core, houses the University of Toronto, Toronto Metropolitan University, the MaRS Centre, and several hospitals, creating an unparalleled concentration of research and clinical excellence. MaRS Discovery District occupies 1.5 million square feet and hosts a diverse community of more than 120 tenants, including research labs and global tech companies.
The region hosts major pharmaceutical companies including Sanofi (which opened an Artificial Intelligence Centre of Excellence in Toronto), Takeda Canada, and Roche, alongside innovative biotech companies like Deep Genomics, ProteinQure, BlueRock Therapeutics, Cybin, and Phenomic developing breakthrough AI-driven drug discovery platforms, cell therapies, and precision medicine solutions. Over the last three-and-a-half years, Ontario has seen $4 billion in investments by global biomanufacturers and life sciences companies, with the Ontario government investing $40 million to help local life sciences companies innovate and compete globally.
Why Toronto Biotech Choose Anilocus
- Collaborative network access – Established partnerships and working relationships with Toronto’s leading research institutions including University of Toronto, MaRS Discovery District, and the Discovery District hospital network
- Specialized in vivo capabilities – Advanced in vivo assessments and expertise that complement safety and efficacy therapeutics testing in Canada’s most concentrated biotech environment
- Integrated preclinical solutions – Comprehensive study design through regulatory submission support, reducing vendor management complexity and accelerating development timelines in Ontario’s innovation hub
CRO Excellence in the Discovery District
Anilocus specializes in preclinical research solutions that meet the demanding standards of Toronto’s pharmaceutical industry. Our capabilities span in vivo studies, pharmacodynamics, pharmacokinetics, behavioral neuroscience, advanced bioanalytics, and regulatory-compliant study execution. What sets us apart is our unique combination of scientific precision and custom fabrication capabilities, delivering exactly what your research requires in a city that witnessed the largest growth in tech jobs in North America between 2015 and 2020.
Operating in Toronto means being part of the Discovery District, built on the historic site where insulin was first administered to a diabetic patient and home to numerous medical breakthroughs including the discovery of insulin and heparin. Our preclinical studies are designed with this innovation-rich environment in mind, ensuring seamless integration with the region’s cutting-edge research infrastructure that includes the University of Toronto’s world-class research facilities and MaRS’s state-of-the-art incubation capabilities.
With Toronto’s life sciences employment reaching 30,490 in 2023 (a 35% increase from 2022) and major expansions like OmniaBio’s planned 400,000 square feet CDMO facility – Canada’s largest exclusively dedicated to cell and gene therapies – the region continues to strengthen its position as Canada’s premier biotech destination. Anilocus is perfectly positioned to support this growth with specialized preclinical services that bridge the gap between laboratory discoveries and clinical applications in Canada’s innovation capital.
Ready to Accelerate Your Research?
Ready to advance your preclinical research with a CRO partner that understands the unique advantages and collaborative spirit of Toronto’s biotech ecosystem? From the innovation corridors of the Discovery District to the cutting-edge facilities at MaRS, Anilocus delivers the scientific excellence that forward-thinking Canadian biotech companies demand.
Get Started Today!
Transform your research vision into actionable data with Anilocus, where scientific precision meets fabrication capability for real research impact in Canada’s premier life sciences hub. Contact us today and speak to a scientist!
